USANA Health Sciences, Inc. (USNA) Income Statement

The quarterly pattern shows alternating signs of life and relapse: mid-2025 posted sequential growth of 9-11% year over year, yet by 2026Q2 growth reversed to -5.3%, which suggests the mid-2025 uptick was more episodic than a genuine inflection. For a direct-selling nutrition business, this volatility most plausibly reflects Associate/Distributor activity swings rather than end-consumer demand stability, making forward revenue inherently harder to extrapolate. Analysts should watch whether 2026's sequential softness persists into the back half, since two consecutive declining quarters would shift the characterization from 'cyclical churn' to 'secular contraction.'

The 2-4 point swing in gross margin across periods appears linked to revenue mix and promotional intensity rather than input cost inflation, since COGS moved proportionally with sales. Maintaining a ~78% gross margin in a category where peers cluster at 69-73% implies meaningful brand equity and distributor loyalty, but the gradual downward drift warrants monitoring; further erosion below ~75% would undermine the pricing-power narrative that supports USANA's premium positioning. Notably, USNA still out-earns NUS at the gross line by ~9 points, which provides a cushion against the operating losses seen in 2026Q2.

The roughly 50% sequential reduction in SG&A appears to reflect a structural realignment rather than ordinary expense management, since it occurred abruptly and held steady thereafter. This reset mechanically lifted operating margins through 2025Q4 (7.6%) despite softer sales, but 2026Q1 and 2026Q2 show the benefit is exhausted: SG&A of $82-88M now exceeds what a ~$220-250M revenue base can absorb when growth turns negative. The implication is that USANA's fixed-cost floor has been lowered but not eliminated, and any further revenue deterioration now flows almost entirely to the operating line, raising the stakes on stabilizing the top line.